Freshfields’ Litigation Team successfully represented Sumitovant Biopharma Limited. A shareholder’s attempt to challenge a $2.9 billion take-private merger between Sumitovant Biopharma Limited (Sumitovant, formerly known as...
This content is for Standard 1 Year members only. LoginJoin Now